OptimizeRx Corporation provided earnings guidance for the first quarter of 2024, for the quarter, the company expects revenue to increase over 40% year-over-year and come in between $18.5 million and $19.2 million with a GAAP net loss between $8.2 million - $7.0 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.06 USD | -0.33% | -6.80% | -15.72% |
May. 14 | Transcript : OptimizeRx Corporation, Q1 2024 Earnings Call, May 14, 2024 | |
May. 14 | OptimizeRx Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-15.72% | 220M | |
+22.55% | 426B | |
+31.87% | 276B | |
+4.92% | 135B | |
+6.46% | 92.01B | |
+23.70% | 89.16B | |
+57.95% | 58.86B | |
+11.34% | 45.03B | |
+19.19% | 34.77B | |
-10.48% | 31.93B |
- Stock Market
- Equities
- OPRX Stock
- News OptimizeRx Corporation
- OptimizeRx Corporation Provides Earnings Guidance for the First Quarter of 2024